…
iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. The company also develops, produces, and distributors of branded cannabis products under the MPX, Anthologie, Black Label, Cheetah, Frutful, GrowHealthy, and The Vault brand names. It offers cannabis flower and trims, such as packaged flowers and pre-rolls; cannabis infused products, including topical creams and edibles; products with cannabis extracts, such as vape cartridges, concentrates, live resins, wax products, oils, and tinctures. The company was formerly known as Ianthus Capital Management LLC and changed its name to iAnthus Capital Holdings, Inc. in September 2016. iAnthus Capital Holdings, Inc. was founded in 2014 and is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
iAnthus Capital Holdings Inc is a company that has operated licensed cannabis cultivation and retail businesses in the United States, offering exposure to state-regulated marijuana markets. Long-term growth drivers include expansion of legal cannabis markets, license consolidation and scaling of retail and production, which may benefit from easing federal policy and consumer adoption.
Key risks include regulatory and legal uncertainty, past financial distress and restructuring-related liabilities, low liquidity and limited public disclosure as a Pink Sheets issuer, and execution risk in stabilizing operations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -23.57M | -25.31M | -59.92M | -438.70M | -54.00M |
| Net income | -40.91M | -7.64M | -76.62M | -449.39M | -76.25M |
| Selling general administrative | 54.31M | 56.28M | 73.17M | 107.59M | 96.97M |
| Selling and marketing expenses | 4.32M | 3.59M | 4.35M | 4.80M | - |
| Gross profit | 47.22M | 75.11M | 63.17M | 74.43M | 111.28M |
| Reconciled depreciation | 19.29M | 24.74M | 27.00M | 31.39M | 31.04M |
| Ebit | -14.59M | -3.35M | -29.76M | -70.22M | -14.11M |
| Ebitda | 5.04M | 20.20M | -2.59M | -25.02M | 16.93M |
| Depreciation and amortization | 19.63M | 23.55M | 27.17M | 45.20M | 31.04M |
| Operating income | -14.59M | -8.51M | -40.71M | -70.22M | -14.11M |
| Other operating expenses | 156.21M | 176.08M | 199.95M | 233.43M | 219.22M |
| Interest expense | 21.49M | 21.80M | 30.16M | 22.25M | 32.67M |
| Tax provision | 17.04M | -17.68M | 9.12M | 10.69M | 22.25M |
| Interest income | 13.75M | 5.16M | 11.37M | 0.09M | 0.52M |
| Net interest income | -7.74M | -16.64M | -37.90M | -22.16M | -32.16M |
| Income tax expense | 17.34M | -17.68M | 16.70M | 10.69M | 22.25M |
| Total revenue | 143.99M | 167.57M | 159.24M | 163.21M | 203.02M |
| Total operating expenses | 60.89M | 83.63M | 103.88M | 144.65M | 127.48M |
| Cost of revenue | 99.29M | 92.45M | 96.07M | 88.78M | 91.73M |
| Total other income expense net | -8.98M | -16.80M | -19.21M | -368.48M | -39.89M |
| Net income from continuing ops | -40.20M | -7.64M | -98.05M | -449.39M | -76.25M |
| Net income applicable to common shares | - | - | - | -449.39M | -76.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 255.99M | 271.04M | 277.41M | 303.47M | 346.74M |
| Intangible assets | 67.48M | 72.86M | 105.37M | 117.05M | 139.06M |
| Other current assets | 8.40M | 27.52M | 2.41M | 0.20M | 1.60M |
| Total liab | 359.03M | 336.58M | 339.07M | 292.48M | 369.14M |
| Total stockholder equity | -103.04M | -65.54M | -61.67M | 10.99M | -22.40M |
| Other current liab | 45.05M | 62.40M | 103.26M | 50.22M | 0.02M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -1375.48M | -1335.28M | -1327.64M | -1251.02M | -800.39M |
| Other liab | - | - | - | 23.82M | 27.51M |
| Good will | 1.56M | 6.15M | 0.00M | - | - |
| Other assets | 12.45M | 28.09M | -12.85M | 6.33M | 16.77M |
| Cash | 11.65M | 18.54M | 13.10M | 14.34M | 13.24M |
| Total current liabilities | 68.51M | 75.29M | 125.43M | 92.57M | 285.82M |
| Current deferred revenue | - | - | 1.09M | 23.82M | 99.45M |
| Net debt | 215.91M | 191.92M | 187.90M | 169.60M | 215.29M |
| Short term debt | 7.20M | 0.07M | 7.77M | 7.84M | 172.72M |
| Short long term debt | - | 0.07M | 0.06M | 0.05M | 165.38M |
| Short long term debt total | 227.56M | 210.46M | 201.00M | 183.94M | 228.54M |
| Other stockholder equity | 1270.13M | 1269.74M | 1265.98M | 1262.01M | 777.99M |
| Property plant equipment | - | 111.50M | 121.38M | 131.72M | 143.06M |
| Total current assets | 48.73M | 74.59M | 45.51M | 50.62M | 55.40M |
| Long term investments | 0.84M | 0.86M | 0.73M | 0.23M | 0.57M |
| Net tangible assets | - | - | - | -106.06M | -161.46M |
| Short term investments | - | 0.00M | - | 0.23M | - |
| Net receivables | 6.43M | 5.54M | 4.61M | 4.00M | 3.60M |
| Long term debt | 193.99M | 182.26M | 165.22M | 147.26M | 28.00M |
| Inventory | 22.25M | 22.47M | 25.38M | 29.80M | 30.45M |
| Accounts payable | 16.27M | 12.83M | 14.40M | 10.69M | 13.64M |
| Non currrent assets other | 3.21M | 5.03M | 4.41M | -19.97M | -18.86M |
| Non current assets total | 207.25M | 196.41M | 231.90M | 252.84M | 291.34M |
| Capital lease obligations | 33.97M | 28.13M | 35.73M | 36.62M | 35.16M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -6.28M | -4.86M | -4.74M | -21.32M |
| Change to liabilities | - | - | - | 0.00M | 1.55M |
| Total cashflows from investing activities | 2.30M | -6.28M | -3.63M | -4.74M | -21.32M |
| Net borrowings | -12.37M | -0.06M | -0.05M | 23.89M | 10.93M |
| Total cash from financing activities | -12.67M | -0.34M | -0.62M | 22.06M | 10.24M |
| Change to operating activities | - | - | - | - | 22.09M |
| Net income | -14.09M | -7.64M | -76.62M | -449.39M | -76.25M |
| Change in cash | -7.23M | 5.92M | -1.23M | -2.17M | 5.07M |
| Begin period cash flow | 19.10M | 13.18M | 14.41M | 16.58M | 11.51M |
| End period cash flow | 11.87M | 19.10M | 13.18M | 14.41M | 16.58M |
| Total cash from operating activities | 3.15M | 12.54M | 3.02M | -19.50M | 16.15M |
| Depreciation | 19.29M | 24.74M | 27.17M | 31.39M | 31.04M |
| Other cashflows from investing activities | 26.07M | -0.76M | 0.01M | -0.09M | -1.19M |
| Change to inventory | -4.57M | 1.57M | 2.78M | -1.11M | -6.90M |
| Change to account receivables | 4.45M | -1.76M | -0.83M | -0.47M | -0.16M |
| Sale purchase of stock | - | -0.28M | -0.57M | - | - |
| Other cashflows from financing activities | -0.09M | -0.28M | -0.57M | 22.43M | 10.31M |
| Change to netincome | - | - | - | 378.24M | 35.70M |
| Capital expenditures | 23.78M | 5.52M | 6.08M | 7.05M | 20.40M |
| Change in working capital | 9.44M | -5.60M | 25.87M | 16.68M | 16.59M |
| Stock based compensation | 1.84M | 2.11M | 4.54M | 30.43M | 6.52M |
| Other non cash items | -13.34M | 19.21M | 25.56M | 359.18M | 42.86M |
| Free cash flow | -20.63M | 7.03M | -3.06M | -26.55M | -4.25M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ITHUF iAnthus Capital Holdings Inc |
- -% |
0.00 | - | - | 0.20 | 2.24 | 2.02 | 33.63 |
| MKKGY Merck KGaA ADR |
-0.22 0.66% |
33.17 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.76 1.62% |
167.12 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.17 0.80% |
21.02 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.85 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States. The company also develops, produces, and distributors of branded cannabis products under the MPX, Anthologie, Black Label, Cheetah, Frutful, GrowHealthy, and The Vault brand names. It offers cannabis flower and trims, such as packaged flowers and pre-rolls; cannabis infused products, including topical creams and edibles; products with cannabis extracts, such as vape cartridges, concentrates, live resins, wax products, oils, and tinctures. The company was formerly known as Ianthus Capital Management LLC and changed its name to iAnthus Capital Holdings, Inc. in September 2016. iAnthus Capital Holdings, Inc. was founded in 2014 and is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert R. Galvin | Interim CEO & COO | 1961 |
| Mr. Philippe Faraut | Chief Financial Officer | 1969 |
| Ms. Megan W. Kulick CFA | VP of Investor Relations | NA |
| Mr. Andrew R. Ryan Esq. | Gen. Counsel | NA |
| Mr. Michael R. Woolston | Sr. VP of Manufacturing, Supply Chain & Quality | NA |
| Mr. Richard Proud | CEO & Director | 1980 |
| Mr. Jason Ware | Chief Financial Officer | 1974 |
| Mr. Andrew R. Ryan Esq. | General Counsel | NA |
| Mr. Michael Piermont | Chief Commercial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.